Scalper1 News
Cubist Pharmaceuticals (CBST) reported good results from a late-stage trial of its new antibiotic Monday morning, sending Cubist stock gapping up 5.5% on the stock market today. The trial compared ceftolozane/tazobactam, known in the industry as tol/taz, to meropenem (sold by AstraZeneca (AZN) as Monan or Meronem) in patients with complicated intra-abdominal infections (cIAI). The company said the trial met its primary endpoint of showing Scalper1 News
Scalper1 News